What CCM Eye HA Plus Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for conditions involving dryness and irritation, often associated with Dry Eye Disease. Ingredients like this may be considered relevant when supportive symptom management is appropriate for the condition. The active ingredient may be part of symptomatic management within this therapeutic area.

CCM Eye HA Plus is commonly used to help with the physical discomfort of dryness, grittiness, stinging, and burning. It is relevant across conditions involving episodic or fluctuating manifestations of surface irritation, such as those caused by prolonged screen time or exposure to dry environments. This use supports patients during difficult episodes by easing distress and may assist with maintaining functional stability during routine activities.

---

Quick Fact: Relevant for Managing Ocular Discomfort This supportive treatment is commonly used to help manage symptoms related to physical discomfort and irritative states of the eye surface.

The eligibility profile for CCM Eye HA Plus is determined by official regulatory documents, primarily focusing on local tolerance and specific patient demographics.

Eligibility Scope	Official Regulatory Statement
Populations for whom use is contraindicated	The medicine is contraindicated for any patient with a known allergy or hypersensitivity to Sodium Hyaluronate or any other ingredient in the formulation.
Age-related eligibility rules	Use is established in the adult population (age 18 and over). Use is not recommended in pediatric patients due to insufficient clinical data, requiring specialist consultation.
Pregnancy and lactation eligibility	For women who are pregnant or breastfeeding, official documentation generally advises consulting an ophthalmologist before use, reflecting a lack of adequate, controlled human studies.
Eligibility-related restrictions	Use is generally restricted in the presence of an active ocular infection and should only proceed with medical clearance. Use in patients with hepatic or renal impairment is typically not restricted but requires specialist consultation.

Official regulatory documents define eligibility by establishing one absolute contraindication (Hypersensitivity). All other rules classify special groups (Pediatric, Pregnant/Lactating) under the Restricted/Conditional Use category, emphasizing the need for professional medical assessment due to limited dedicated data.

The official interaction profile for CCM Eye HA Plus is determined by its characteristics as a locally acting Ocular Lubricant with negligible systemic absorption. Regulatory documentation establishes that the primary concern is a procedural interaction involving topical administration, rather than systemic pharmacological effects.

---

Absence of Documented Systemic Interactions

Official regulatory statements consistently confirm the absence of systemic interactions for this product. This includes:

• Metabolic Interactions: There are no documented warnings regarding interactions with Cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp).
• Systemic Pharmacodynamic Effects: No additive or synergistic systemic effects are noted in official labeling when this product is combined with other oral or injectable treatments.
• Food and Substance Interactions: No interactions with food, alcohol, or herbal products are documented in regulatory prescribing information.

---

Required Timing-Based Interaction

• The only relevant documented interaction is procedural, involving Other Topical Ophthalmic Products. Co-administration with any other eye drops, suspensions, or ointments requires a mandatory time separation.
• This procedural constraint is intended to prevent the physical dilution or wash-out of either preparation, ensuring the product's viscoelastic layer remains intact on the ocular surface. Sequential administration with an observed interval must be followed; simultaneous use is restricted.

The mechanism of CCM Eye HA Plus is entirely biophysical, relying on the unique physical properties of the Sodium Hyaluronate (HA) polymer to support the rheological and structural stability of the ocular surface, rather than chemical interaction with molecular signaling targets.

---

Rheological Stabilization and Friction Reduction

This domain describes how the HA polymer physically interacts with the ocular surface epithelium and its fluid environment. HA forms a highly viscoelastic protective layer that exhibits shear-thinning behavior. This means the layer maintains high stability and coating ability when the eye is still, yet it thins efficiently during the blink cycle. This action significantly reduces the mechanical shear stress transferred to the surface, which facilitates low-friction eyelid movement.

---

️ Hydrogel Formation and Tear Film Persistence

This mechanism outlines how the active ingredient binds water and remains on the eye. The HA molecule's potent hydrophilic nature allows it to absorb and bind large amounts of water, forming a resilient hydrogel that integrates with the existing tear film structure. Furthermore, HA adheres to the epithelial mucin layer via non-covalent forces, increasing the retention time of the polymer layer. This provides a continuous physiological barrier that actively lowers the evaporation rate of the aqueous tear component, which helps modulate the hydration level of the ocular surface.

How to Use CCM Eye HA Plus

CCM Eye HA Plus is intended for Ophthalmic use only, administered topically to the eye surface. Official instructions define the appropriate application amount and frequency, which is crucial for proper administration.

---

Standard Administration and Dosing

Feature	Official Labeled Instruction
Route of Administration	Ophthalmic (Topical use to the eye surface)
Dose per Application	Instill 1 or 2 drops into the affected eye(s)
Frequency Pattern	As-needed (Symptom-driven, intermittent use) or up to four times daily (some labels permit up to eight times daily)

---

The regimen specifies the instillation of 1 or 2 drops and allows for flexible dosing, permitting both a fixed daily schedule and use driven by symptoms for temporary relief. If a dose is missed, it should be applied unless it is nearly time for the next scheduled dose; instructions specify not to double the dose.

Procedural Instructions and Constraints

To maintain sterility, the container tip must not contact the eye, eyelid, or any other surface during instillation. When this solution is used alongside other ophthalmic drops, a mandatory 5-minute interval must be observed between administrations, with the Sodium Hyaluronate solution typically applied last. Unit-dose containers must be discarded immediately after a single use.

Population-Specific Rules

Usage of this solution is generally not recommended in children under 18 years of age due to insufficient clinical experience documented in this specific population. For older adults, no specific dose adjustment is required. The product is also generally suitable for use while wearing contact lenses.

Research Evidence / Overview of Studies

---

A. Studies on Efficacy

Research has explored the action of CCM Eye HA Plus (containing carboxymethylcellulose and hyaluronic acid) in managing dry eye symptoms. Studies evaluated whether the drug was associated with changes in symptoms and reported that it was evaluated for its potential to affect symptoms at early time points from moderate discomfort.

Trials compared formulations containing hyaluronic acid (HA) and carboxymethylcellulose (CMC) with other treatments or vehicles, frequently using measures like tear break-up time (TBUT), corneal staining scores, and patient-reported indices (such as OSDI).

Findings included statistically significant differences in reported scores, suggesting an association with improvement in both objective signs (like ocular surface staining) and subjective symptoms (such as burning or dryness) over the study periods. The study observed changes over the duration of the trials, suggesting the potential for sustained maintenance of ocular surface parameters.

---

B. Combination Therapy

Clinical trials have evaluated combined therapy approaches using HA and CMC, sometimes alongside other agents like osmoprotectants, in patients with dry eye disease. Research evaluated whether the combined therapy approach was associated with changes in symptoms and whether it was associated with changes in tear film stability relative to monotherapy or physical therapy alone. This combined therapy approach was included in trials alongside other treatments. The study design evaluated the impact of beginning combination therapy shortly after diagnosis on the outcomes reported in the study.

---

C. Safety and Tolerability

Data collected in clinical and post-marketing studies suggested that formulations containing sodium hyaluronate and carboxymethylcellulose generally demonstrate a favorable tolerability profile. The most frequently reported adverse events in studies, when they occurred, were typically mild and transient, such as temporary blurred vision or eye irritation, and were similar to those reported with vehicle-only drops. Study reports included data on tolerability, with adverse events often comparable between the active drug and the vehicle.

Key Studies & References

1. Randomized, Multicenter Clinical Trial Comparing Two Hyaluronic Acid/Carboxymethylcellulose Combination Eye Drops for the Treatment of Dry Eye Disease
2. The Comparative Efficacy and Safety of Hyaluronic Acid and Carboxymethylcellulose for Dry Eye Syndrome: A Network Meta-Analysis of Clinical Trials

Common questions about CCM Eye HA Plus (FAQ)

---

Q: How is CCM Eye HA Plus different from regular lubricating eye drops?

A: Official product information indicates CCM Eye HA Plus is classified as a specialized Viscoelastic Ocular Lubricant. Its mechanism is biophysical, meaning it relies on the physical properties of its ingredients, like Sodium Hyaluronate. This active ingredient forms a highly elastic and durable protective layer that is described as reducing mechanical stress during blinking and increasing the retention time of the polymer layer on the eye's surface.

Q: What are the most commonly reported side effects of CCM Eye HA Plus?

A: Regulatory safety documents characterize adverse reactions as generally local and transient, meaning they are mild and temporary. The most common events documented include ocular discomfort, eye irritation, the sensation of a foreign body in the eye, and temporary blurred vision.

Q: Can CCM Eye HA Plus cause a temporary stinging or burning sensation?

A: Yes, official safety information reports that stinging sensations are documented adverse reactions. These effects are typically classified as transient (short-lasting) and generally occur immediately following instillation as the solution spreads across the eye surface.

Q: Are headaches a potential side effect of using CCM Eye HA Plus?

A: Regulatory safety documents characterize the adverse reactions as generally local and confined to the ocular surface, reflecting negligible systemic absorption. Headaches are not listed among the commonly reported ocular or systemic adverse reactions in the official labeling.

Q: Is blurry vision or mild discomfort immediately after using CCM Eye HA Plus a normal expectation?

A: Yes, temporary blurred vision and ocular discomfort are classified as common, transient effects. Official documents state that these sensations generally resolve quickly immediately following instillation, as the solution settles across the eye surface.

Q: What should be done if the CCM Eye HA Plus solution appears discolored or cloudy?

A: The official storage requirements specify that the product should only be used if the solution is clear and colorless. If the solution appears discolored or cloudy, official guidance states that the product should not be used.

Q: What information is available about using CCM Eye HA Plus during pregnancy?

A: Due to a lack of adequate, controlled human studies in pregnant or breastfeeding women, official documentation generally advises consultation with an ophthalmologist before use.

Q: Is CCM Eye HA Plus intended for long-term or short-term use?

A: Official documents allow for flexible dosing, permitting both use driven by symptoms for temporary relief and fixed daily schedules, suggesting it can be used intermittently or regularly. Research findings have suggested the potential for sustained maintenance of ocular surface parameters during the trials.

Q: How quickly must CCM Eye HA Plus be used after the seal or foil is broken?

A: Because the product is preservative-free and designed for single use, official regulatory instructions indicate that unit-dose containers should be discarded immediately after a single administration. They should not be stored or reused.

Q: Why might a healthcare professional choose CCM Eye HA Plus over similar medicines?

A: The unique biophysical properties of the medicine—such as its high viscoelasticity and ability to increase tear film retention time—are distinguishing characteristics. Research has evaluated its potential to affect both objective signs and subjective symptoms over the study periods.

Q: Are red eyes a side effect of using CCM Eye HA Plus?

A: Red eyes (hyperemia) are not explicitly listed in the regulatory documents among the common or transient ocular adverse reactions. The commonly documented local effects include discomfort, irritation, and temporary blurred vision.

Q: Does CCM Eye HA Plus interact with any common over-the-counter pain relievers?

A: Official regulatory statements consistently confirm the absence of systemic interactions for this product. This means there are no documented warnings in the labeling regarding interactions with oral medications, including common over-the-counter pain relievers.

Q: What should I do if I miss a scheduled application of CCM Eye HA Plus?

A: If a dose is missed, regulatory documents instruct that it should be applied unless it is nearly time for the next scheduled dose. Regulatory documents state that patients should not double the dose to make up for the missed application.

Q: Does using CCM Eye HA Plus affect a person's ability to drive or operate machinery?

A: CCM Eye HA Plus may cause temporary blurred vision immediately following instillation. Official guidelines caution that temporary visual disturbances may occur; patients are advised to wait until their vision clears before driving or operating machinery.

Q: What happens if CCM Eye HA Plus is used after its official expiration date?

A: Official documentation indicates the product should not be used beyond the expiration date listed on the packaging. Unused or expired medication must be disposed of in accordance with local pharmaceutical waste regulations.

Q: Are there any reported interactions between CCM Eye HA Plus and common vitamins or herbal supplements?

A: Official regulatory labeling confirms the absence of documented systemic interactions with food, alcohol, or herbal products. This indicates there are no documented warnings regarding interactions with common vitamins or herbal supplements.

Q: Is CCM Eye HA Plus known to cause dry mouth or changes in taste?

A: The safety profile is characterized by adverse reactions that are generally local and confined to the ocular surface, reflecting negligible systemic absorption. Systemic effects like dry mouth or changes in taste are not noted in the official labeling.

Storage and Disposal of CCM Eye HA Plus

This section outlines the official, regulatory requirements for storing and disposing of CCM Eye HA Plus (Sodium Hyaluronate ophthalmic solution).

---

Storage Requirements

Requirement	Details
Temperature Control	Store at controlled room temperature, typically 15 C to 25 C (59 F to 77 F). Do not freeze.
Protection	Keep out of reach of children. Store in the original carton to protect the single-use containers.
Integrity	Use only if the single-use container is intact and the solution is clear and colorless.

---

Disposal and Stability

As this is a preservative-free, single-use product, the opened container and any remaining solution must be discarded immediately after administration; do not reuse. The product must not be used beyond the expiration date. Unused or expired medication must be disposed of in accordance with local pharmaceutical waste regulations.